Liver X receptor activation restores memory in aged AD mice without reducing amyloid

Neurobiology of Aging

Volumn 32, Issue 7, 2011, Pages 1262-1272

  Vanmierlo, Tim ^a,b   Rutten, Kris ^a   Dederen, Jos ^c   Bloks, Vincent W ^d   van Vark van der Zee, Leonie C ^e   Kuipers, Folkert ^d   Kiliaan, Amanda ^c   Blokland, Arjan ^a   Sijbrands, Eric J G ^e   Steinbusch, Harry ^a   Prickaerts, Jos ^a   Lütjohann, Dieter ^b   Mulder, Monique ^a,e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c RADBOUD UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Abca1; Abcg1; Alzheimer's disease; Amyloid; Apoe; Cholesterol; LXR; T0901317

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE;

AGED; AGING; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DENTATE GYRUS; DISEASE COURSE; GENE TARGETING; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; LONG TERM CARE; MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RECEPTOR UPREGULATION; REGULATORY MECHANISM; TASK PERFORMANCE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; HYDROCARBONS, FLUORINATED; MEMORY; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORPHAN NUCLEAR RECEPTORS; SULFONAMIDES;

EID: 79958773215     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.07.005     Document Type: Article

References (60)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
2. Antoine J.C., Tommasi M., Boucheron S., Convers P., Laurent B., Michel D. Pathology of roots, spinal cord and brainstem in syringomyelia-like syndrome of Tangier disease. J. Neurol. Sci. 1991, 106:179-185.
3. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007, 27:909-918.
4. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
5. Chintagari N.R., Jin N., Wang P., Narasaraju T.A., Chen J., Liu L. Effect of cholesterol depletion on exocytosis of alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 2006, 34:677-687.
6. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
7. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
8. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
9. Dixon W.J. Analyses of extreme values. Ann. Math. Stat. 1959, 21:488-506.
10. Dixon W.J. Ratios involving extreme values. Ann. Math. Stat. 1959, 22:68-78.
11. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
12. Eckert G.P., Vardanian L., Rebeck G.W., Burns M.P. Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 2007, 423:47-52.
13. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 2008, 28:11500-11510.
14. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2008.
15. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 1996, 6:986-994.
16. Hirsch-Reinshagen V., Burgess B.L., Wellington C.L. Why lipids are important for Alzheimer disease?. Mol. Cell. Biochem. 2008.
17. Hooijmans C.R., Graven C., Dederen P.J., Tanila H., van Groen T., Kiliaan A.J. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res. 2007, 1181:93-103.
18. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
19. Jansen P.J., Lutjohann D., Abildayeva K., Vanmierlo T., Plosch T., Plat J., von Bergmann K., Groen A.K., Ramaekers F.C., Kuipers F., Mulder M. Dietary plant sterols accumulate in the brain. Biochim. Biophys. Acta. 2006.
20. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
21. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
22. Kohler C., Ebert U., Baumann K., Schroder H. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol. Dis. 2005, 20:528-540.
23. Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., Lazo J.S. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 2005, 280:4079-4088.
24. Kotti T., Head D.D., McKenna C.E., Russell D.W. Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11394-11399.
25. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7238-7243.
26. Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 2006, 185:33-42.
27. Lutjohann D., Brzezinka A., Barth E., Abramowski D., Staufenbiel M., von Bergmann K., Beyreuther K., Multhaup G., Bayer T.A. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J. Lipid Res. 2002, 43:1078-1085.
28. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
29. Marx C.E., Keefe R.S., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L., Shampine L.J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in Schizophrenia. Neuropsychopharmacology 2009.
30. Marx J. Alzheimer's disease. Bad for the heart, bad for the mind?. Science 2001, 294:508-509.
31. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
32. Meaney S., Heverin M., Panzenboeck U., Ekstrom L., Axelsson M., Andersson U., Diczfalusy U., Pikuleva I., Wahren J., Sattler W., Bjorkhem I. Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 2007, 48:944-951.
33. Milagre I., Nunes M.J., Gama M.J., Silva R.F., Pascussi J.M., Lechner M.C., Rodrigues E. Transcriptional regulation of the human CYP46A1 brain-specific expression by Sp transcription factors. J. Neurochem. 2008, 106:835-849.
34. Mitro N., Vargas L., Romeo R., Koder A., Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 2007, 581:1721-1726.
35. Mukai H., Tsurugizawa T., Ogiue-Ikeda M., Murakami G., Hojo Y., Ishii H., Kimoto T., Kawato S. Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology 2006, 84:255-263.
36. Mulder M., Jansen P.J., Janssen B.J., van de Berg W.D., van der Boom H., Havekes L.M., de Kloet R.E., Ramaekers F.C., Blokland A. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol. Dis. 2004, 16:212-219.
37. Mulder M., Terwel D. Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: a role for high-density lipoproteins?. Haemostasis 1998, 28:174-194.
38. Plosch T., Kok T., Bloks V.W., Smit M.J., Havinga R., Chimini G., Groen A.K., Kuipers F. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J. Biol. Chem. 2002, 277:33870-33877.
39. Rebeck G.W. Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J. Mol. Neurosci. 2004, 23:219-224.
40. Repa J.J., Li H., Frank-Cannon T.C., Valasek M.A., Turley S.D., Tansey M.G., Dietschy J.M. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 2007, 27:14470-14480.
41. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., Kubek K., Hirst W.D., Gonzales C., Chen Y., Murphy E., Leonard S., Vasylyev D., Oganesian A., Martone R.L., Pangalos M.N., Reinhart P.H., Jacobsen J.S. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
42. Rutten K., Vente J.D., Sik A., Ittersum M.M., Prickaerts J., Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav. Brain Res. 2005, 164:11-16.
43. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
44. Shafaati M., Solomon A., Kivipelto M., Bjorkhem I., Leoni V. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci. Lett. 2007, 425:78-82.
45. Shobab L.A., Hsiung G.Y., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4:841-852.
46. Shukla C., Bridges L.R. Regional distribution of tau, beta-amyloid and beta-amyloid precursor protein in the Alzheimer's brain: a quantitative immunolabelling study. Neuroreport 1999, 10:3785-3789.
47. Sik A., van Nieuwehuyzen P., Prickaerts J., Blokland A. Performance of different mouse strains in an object recognition task. Behav. Brain Res. 2003, 147:49-54.
48. Snowdon D.A. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist 1997, 37:150-156.
49. Sun Y., Yao J., Kim T.W., Tall A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 2003, 278:27688-27694.
50. Tint G.S., Seller M., Hughes-Benzie R., Batta A.K., Shefer S., Genest D., Irons M., Elias E., Salen G. Markedly increased tissue concentrations of 7-dehydrocholesterol combined with low levels of cholesterol are characteristic of the Smith-Lemli-Opitz syndrome. J. Lipid Res. 1995, 36:89-95.
51. Toledo J.D., Tricerri M.A., Corsico B., Garda H.A. Cholesterol flux between lipid vesicles and apolipoprotein AI discs of variable size and composition. Arch. Biochem. Biophys. 2000, 380:63-70.
52. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., Selkoe D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006, 60:668-676.
53. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., Paul S.M., Holtzman D.M. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118:671-682.
54. Wang N., Yvan-Charvet L., Lutjohann D., Mulder M., Vanmierlo T., Kim T.W., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. Faseb J. 2007.
55. Whitney K.D., Watson M.A., Collins J.L., Benson W.G., Stone T.M., Numerick M.J., Tippin T.K., Wilson J.G., Winegar D.A., Kliewer S.A. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol. 2002, 16:1378-1385.
56. Wolozin B., Brown J., Theisler C., Silberman S. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev. 2004, 10:127-146.
57. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 2008, 29:422-437.
58. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18700-18705.
59. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10601-10606.
60. Zhang M., Strnatka D., Donohue C., Hallows J.L., Vincent I., Erickson R.P. Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc1(-/-) mice. J. Neurosci. Res. 2008.